Track TriSalus Life Sciences Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

TriSalus Life Sciences Inc. Common Stock TLSI · Stock Open TriSalus Life Sciences Inc. Common Stock in new tab

2.43 USD
EPS
-0.41
P/B
229.09
Beta
0.51
Target Price
7.75 USD
Loading chart...
Key Metrics
Earnings dateMarch 4, 2027
EPS-0.41
Book Value0.01
Price to Book229.09
Debt/Equity4954.56
% Insiders33.893%
Growth
Revenue Growth0.11%
Estimates
Forward P/E-10.08
Forward EPS-0.25
Target Mean Price7.75

DCF valuation

Model fair value for TriSalus Life Sciences Inc. Common Stock (TLSI)
Result
Sign in to run the valuation for TLSI.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus Strong buy · mean target 7.75 USD (low 4.00, high 11.00) · as of 13 Nov 2026
Low 4.00
Mean 7.75
High 11.00
Price 2.43
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

TriSalus Life Sciences Inc. Common Stock Logo TriSalus Life Sciences Inc. Common Stock Analysis (TLSI)

United States Health Care Official Website Stock

Is TriSalus Life Sciences Inc. Common Stock a good investment? TriSalus Life Sciences Inc. Common Stock (TLSI) is currently trading at 2.43 USD. Market analysts have a consensus price target of 7.75 USD. This suggests a potential upside from current levels.

Earnings Schedule: TriSalus Life Sciences Inc. Common Stock is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is -0.25.

Investor FAQ

Does TriSalus Life Sciences Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is TriSalus Life Sciences Inc. Common Stock?

TriSalus Life Sciences Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of -0.41.

Company Profile

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Exchange Ticker
NMS (United States) TLSI
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion